Publication: Allogeneic Peripheral Blood Stem Cell Transplantation in Children with Homozygous β-Thalassemia and Severe β-Thalassemia/Hemoglobin E Disease
Issued Date
2004-04-01
Resource Type
ISSN
10774114
Other identifier(s)
2-s2.0-30244517332
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Pediatric Hematology/Oncology. Vol.26, No.4 (2004), 248-252
Suggested Citation
Samart Pakakasama, Suradej Hongeng, Wattana Chaisiripoomkere, Ampaiwan Chuansumrit, Nongnuch Sirachainun, Saengsuree Jootar Allogeneic Peripheral Blood Stem Cell Transplantation in Children with Homozygous β-Thalassemia and Severe β-Thalassemia/Hemoglobin E Disease. Journal of Pediatric Hematology/Oncology. Vol.26, No.4 (2004), 248-252. doi:10.1097/00043426-200404000-00007 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/21675
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Allogeneic Peripheral Blood Stem Cell Transplantation in Children with Homozygous β-Thalassemia and Severe β-Thalassemia/Hemoglobin E Disease
Other Contributor(s)
Abstract
To determine the outcome of children with homozygous β-thalassemia (β/β) and severe β-thalassemia/hemoglobin E disease (β/E) who underwent allogeneic peripheral blood stem cell transplantation (PBSCT). The authors conducted a cohort study of allogeneic PBSCT in β/β and β/E patients who had 6/6 or 5/6 HLA-matched sibling donors. All patients received a conditioning regimen including busulfan and cyclophosphamide, except one who received busulfan and cyclophosphamide plus antithymocyte globulin. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine A and methotrexate for eight patients and cyclosporine and mycophenolate mofetil for one patient. Donors received G-CSF for 4 days before leukapheresis collections. There were five β/β and four β/E patients in this study. The median age was 9 years (range 1.5-10 years). The median CD34+ cell count was 7. 4 × 106 cells/kg recipient body weight. All patients achieved neutrophil and platelet engraftment with a median time of 15 days and 21 days respectively. Acute GVHD grade 2 to 4 appeared in four patients (grade 2, n = 3; grade 4, n = 1). Three patients developed chronic GVHD (limited, n = 2; extensive, n = 1). All patients were alive with a median follow-up time of 23 months (range 7-52 months). Neither graft failure nor graft rejection was observed. Allogeneic PBSCT is feasible for children with β/β and β/E, although the incidence of GVHD was apparently high compared with bone marrow transplant study in Thais.